SOURCE: InVivo Therapeutics

InVivo Therapeutics

April 07, 2011 10:22 ET

InVivo Therapeutics Presents Data on Novel Hydrogel Technology in Spinal Cord Injury and Neurosurgical Applications at 2011 AANS 79th Annual Scientific Meeting

Proprietary PEG-Based Technology Overcomes Limitations of Current Synthetic Biopolymeric Hydrogels

CAMBRIDGE, MA--(Marketwire - April 7, 2011) - InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that a poster highlighting data from a laboratory investigation of the company's injectable hydrogel technology for local, controlled-release drug delivery, is being presented at the 79th Annual Meeting of the American Association of Neurological Surgeons (AANS), which is being held April 9-13 in Denver, Colorado.

The laboratory investigation, "An injectable thiol-acrylate poly(ethylene glycol) hydrogel for sustained release of small-molecule therapeutics in intraparenchymal and peridural application," was designed to evaluate the potential of a system of controlled chemical gelation for an injectable polyethylene glycol (PEG)-based hyrdogel that was designed to overcome challenges associated with existing synthetic polymeric hydrogels.

"Synthetic polymeric hydrogels present a promising technology platform for therapeutic intervention in a wide range of diseases and traumatic injuries, but limitations associated with current options include post-injection swelling and a limited ability to guide cellular interactions," said Eric J. Woodard, MD, InVivo's Chief Medical officer and Chief of Neurosurgery at New England Baptist Hospital, who co-authored the study. "InVivo's novel, PEG-based polymeric hydrogel addresses the engineering challenges of injectable in situ gelling materials, resulting in a number of desirable properties, including absence of swelling and compatibility with human tissues."

Woodard continued: "Furthermore, in vitro studies demonstrate the hydrogel's potential for promoting cell adhesion, indicating the technology's potential to treat not just the symptoms of SCI, but its underlying neurological cause. We look forward to further investigating the potential of this technology to provide an urgently needed new treatment option for patients with SCI."

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 10-K. We do not undertake to update these forward-looking statements made by us.

Contact Information

  • Contacts:
    David Pitts
    Argot Partners
    Email Contact